TP53BP1 and in situ carcinoma: The key findings of this work are an absence of any significant differences of γ-H2AX and 53BP1 foci levels between patients and healthy controls and no correlation of γ-H2AX and 53BP1 levels with MRI measures of MS and the EDSS in patients with CIS/early RRMS.